Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,010 people get BMRN articles and Market Currents by email alert.
Get email alerts on BMRN »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
GlobeNewswire (Mon, 9:00AM)
-
GlobeNewswire (Thu, 5:49PM)
-
-
GlobeNewswire (May 14, 2013)
-
GlobeNewswire (May 2, 2013)
-
-
GlobeNewswire (Apr 25, 2013)
-
GlobeNewswire (Apr 24, 2013)
-
-
-
GlobeNewswire (Apr 18, 2013)
-
-
GlobeNewswire (Apr 1, 2013)
-
GlobeNewswire (Apr 1, 2013)
-
To learn more about Seeking Alpha Pro, click here.
-
-
BioMarin's Expanding Product Portfolio Will Lead To Gains In 2013PropThink • Mon, Dec 31, 2012
-
-
What's To Come At BioMarinChimera Research Group • Thu, Aug 2, 2012 -
How Much Further Can Rare Diseases Carry BioMarin?Stephen Simpson • Thu, Mar 29, 2012 -
-
BioMarin Pipeline UpdateZacks Investment Research • Wed, Sep 1, 2010 -
BioMarin Rolls the Dice on a New Lupus DrugEben Tessari • Thu, Jan 8, 2009 -
Smallcap BioMarin's Drug Kuvan Showing Great PromiseNotable Calls • Tue, Feb 12, 2008 -
Look Who's Buying Shares of BioMarin PharmaceuticalLon Juricic • Tue, Jun 19, 2007 -
BioMarin Recieves Approval for Aldurazyme in JapanH.S. Ayoub • Wed, Nov 1, 2006
-
-
-
-
-
-
-
-
-
-
-
-
-
4 Biotech Stocks On The ClockStock Traders Daily • Tue, Feb 19 -
-
-
-
-
7 High Growth Healthcare Stocks With Strong Inventory TrendsKapitall • Wed, Dec 12, 2012 -
-
-
BioMarin Pharmaceutical Inc. Q2 2009 Earnings Call TranscriptThu, Jul 30, 2009
-
BioMarin Pharmaceutical Inc., Q1 2009 Earnings Call TranscriptFri, May 1, 2009
-
BioMarin Pharmaceutical Inc. Q4 2008 Earnings Call TranscriptWed, Feb 18, 2009
-
BioMarin Pharmaceutical Inc. Q3 2008 Earnings Conference Call TranscriptTue, Oct 28, 2008
-
BioMarin Pharmaceutical, Inc. Q2 2008 Earnings Call TranscriptWed, Aug 6, 2008
-
BioMarin Pharmaceutical, Inc. Q1 2008 Earnings Call TranscriptWed, Apr 30, 2008
-
BioMarin Pharmaceutical, Inc. Q4 2007 Earnings Call TranscriptTue, Mar 4, 2008
-
GlobeNewswire (Mon, 9:00AM)
-
GlobeNewswire (Thu, 5:49PM)
-
GlobeNewswire (May 14, 2013)
-
GlobeNewswire (May 2, 2013)
-
GlobeNewswire (Apr 25, 2013)
-
GlobeNewswire (Apr 24, 2013)
-
GlobeNewswire (Apr 18, 2013)
-
at CNBC.com (Apr 1, 2013)
-
GlobeNewswire (Apr 1, 2013)
-
GlobeNewswire (Apr 1, 2013)
-
GlobeNewswire (Mar 25, 2013)
-
at MarketWatch.com (Mar 22, 2013)
-
GlobeNewswire (Mar 19, 2013)
-
GlobeNewswire (Mar 19, 2013)
-
GlobeNewswire (Mar 18, 2013)
-
at CNBC.com (Mar 15, 2013)
-
at CNBC.com (Feb 22, 2013)
-
GlobeNewswire (Feb 21, 2013)
BMRN vs. ETF Alternatives
Company Description
Currently, there's no company description for BMRN.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Monday, July 2, 2012, 2:38 PM Piper Jaffray looks at other potential takeout candidates in the biotech space post-Amylin, highlighting BioMarin (BMRN +3.8%), Affymax (AFFY +1%), Theravance (THRX +8.3%), and Rigel Pharmaceuticals (RIGL +2.3%) all as potential candidates. Piper notes that BioMarin could fetch as much as $79 per share, and notes that Japanese drug heavyweight Takeda Pharmaceuticals (TKPYY.PK) could be the most likely suitor for Affymax. Comment! [Healthcare, On the Move, M&A]
- Tuesday, June 12, 2012, 9:07 AM BioMarin Pharmaceutical (BMRN) +4.8% premarket on rumors that Glaxo (GSK) is in advanced discussions toward a $5B buyout of BMRN. Last week, Shire (SHPGY, SHPGF.PK) also was said to be stalking the company. Glaxo is already engaged in a hostile $2.6B takeover bid for Human Genome Sciences. Comment! [Healthcare, M&A, On the Move]
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
freefdawatchlist
http://stks.co/kDzg Bearish call on $BMRN, 3k patient cannot generate 775 million in 2015. Its a sell with PT of 40. $PCYC" $BMRN - View all 0 replies
-
freefdawatchlist
http://stks.co/kDzs Pharmacyclics is not worth $51.30 with no FDA approved drug. Ideally its should be below 10. $PCYC $BMRN" - View all 0 replies
-
freefdawatchlist
http://bit.ly/RNQTMf Bearish call on $BMRN, 3k patient cannot generate 775 million in 2015. Its a sell with PT of 40. - View all 0 replies
-
freefdawatchlist
http://bit.ly/SNycwr Premarket Gainer and Loser for Nov 5th: $BMRN, $NTE, $EQU, $SF, $MAPP, $MEI, $MEG, $RDN - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
ZetaKap
3 Mid Cap Stocks Loaded With Cash And Set To Grow http://bit.ly/PLDPXE $BMRN $CBST $KNM @ZetaKap - View all 0 replies
LATEST REPLIES
-
- View all 1 replies
-
Michael Webb: Bacterin is definitely a Buy! Now if they could only do a better job of informing investors of how truly ground breaking their tech is.